Assessment of glutamate and glutamine contribution to in vivo N-acetylaspartate quantification in human brain by1H-magnetic resonance spectroscopy

Magnetic Resonance in Medicine

Volumn 54, Issue 6, 2005, Pages 1333-1339

  Clementi, Valeria ^a   Tonon, Caterina ^a   Lodi, Raffaele ^a   Malucelli, Emil ^a   Barbiroli, Bruno ^a   Iotti, Stefano ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Glx; Hepatic encephalopathy; Magnetic resonance spectroscopy; Metabolite quantification; N acetylaspartate

Indexed keywords

AMINO ACIDS; MAGNETIC RESONANCE SPECTROSCOPY; MAGNETISM; METABOLITES; NEURODEGENERATIVE DISEASES;

1H MAGNETIC RESONANCE SPECTROSCOPIES; CLINICAL SETTINGS; HEALTHY CONTROLS; HEPATIC ENCEPHALOPATHIES; LOW MAGNETIC FIELDS; MODEL SOLUTION; N-ACETYLASPARTATE; PERFECT MATCHES;

MAGNETIC RESONANCE;

GLUTAMIC ACID; GLUTAMINE; N ACETYLASPARTIC ACID;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; EVALUATION; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; HYPOTHESIS; IN VIVO STUDY; MALE; NERVE CELL; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE ASSAY; SIGNAL TRANSDUCTION;

EID: 28444482064     PISSN: 07403194     EISSN: None     Source Type: Journal    
DOI: 10.1002/mrm.20703     Document Type: Article

References (39)

1. Taylor DL, Davies SE, Obrenovitch TP, Urenjak J, Richards DA, Clark JB, Symon L. Extracellular N-acetylaspartate in the rat brain: in vivo determination of basal levels and changes evoked by high K+. J Neurochem 1994;62:2349-2355.
2. Bhakoo KK, Pearce D. In vitro expression of N-acetylaspartate by oligodendrocytes: implications for proton magnetic resonance spectroscopy signal in vivo. J Neurochem 2000;74:254-262.
3. Baslow MH. Functions of N-acetyl-L-aspartate and N-acetyl-L-aspartyl- glutamate in the vertebrate brain: role in glial cell-specific signaling. J Neurochem 2000;75:453-459.
4. Dautry C, Vaufrey F, Brouillet E, Bizat N, Henry PG, Conde F, Bloch G, Hantraye P. Early N-acetylaspartate depletion is a marker of neuronal dysfunction in rats and primates chronically treated with the mitochondrial toxin 3-nitropropionic acid. J Cereb Blood Flow Metab 2000; 20:789-799.
5. Jung RE, Yeo RA, Chiulli SJ, Sibbitt WL Jr, Weers DC, Hart BL, Brooks WM. Biochemical markers of cognition: a proton MR spectroscopy study of normal human brain. Neuroreport 1999;10:3327-3331.
6. 1H MRS in acute traumatic brain injury. J Magn Reson Imaging 1998;8:829-840.
7. Lopez-Villegas D, Lenkinski RE, Frank I. Biochemical changes in the frontal lobe of HIV-infected individuals detected by magnetic resonance spectroscopy. Proc Natl Acad Sci USA 1997;94:9854-9859.
8. 1H MRSI-detected hippocampal abnormalities in temporal lobe epilepsy. Neurology 1999;53:2052-2058.
9. Rutgers DR, van der Grond J. Relaxation times of choline, creatine and N-acetylaspartate in human cerebral white matter at 1.5 T. NMR Biomed 2002;15:215-221.
10. Kreis R, Ernst T, Ross B. Absolute quantification of water and metabolites in the human brain. II. Metabolite concentrations J Magn Reson B 1993;102:9-19.
11. Keevil S, Barbiroli B, Brooks J, Cady EB, Canese R, Carlier P, Collins DJ, Gilligan P, Gobbi G, Hennig J, Kugel H, Leach MO, Metzler D, Mlynarik V, Moser E, Newbold MC, Payne GS, Ring P, Roberts JN, Rowland IJ, Thiel T, Tkac I, Topp S, Wittsack HJ, Podo F, et al. Absolute metabolite quantification by in vivo NMR spectroscopy: II. A multicentre trial of protocols for in vivo localised proton studies of human brain. Magn Reson Imaging 1998;16:1093-1106.
12. Provencher SW. Automatic quantitation of localized in vivo 1 H spectra with LCModel. NMR Biomed 2001;14:260-264.
13. Ratiney H, Sdika M, Coenradie Y, Cavassila S, van Ormondt D, Graveron-Demilly D. Time-domain semi-parametric estimation based on a metabolite basis set. NMR Biomed 2005;18:1-13.
14. 1H magnetic resonance in the study of hepatic encephalopathy in humans. Metab Brain Dis 2002;17:415-429.
15. Kreis R, Ross BD, Farrow NA, Ackerman Z. Metabolic disorders of the brain in chronic hepatic encephalopathy detected with H-1 MR spectroscopy. Radiology 1992;182:19-27.
16. Ross BD, Danielsen ER, Bluml S. Proton magnetic resonance spectroscopy: the new gold standard for diagnosis of clinical and subclinical hepatic encephalopathy?. Dig Dis 1996;14:30-39.
17. Barbiroli B, Gaiani S, Lodi R, Iotti S, Tonon C, Clementi V, Donati G, Bolondi L. Abnormal brain energy metabolism shown by in vivo phosphorus magnetic resonance spectroscopy in patients with chronic liver disease. Brain Res Bull 2002;59:75-82.
18. Taylor-Robinson SD. Applications of magnetic resonance spectroscopy to chronic liver disease. Clin Med 2001;1:54-60.
19. Spahr L, Vingerhoets F, Lazeyras F, Delavelle J, DuPasquier R, Giostra E, Mentha G, Terrier F, Hadengue A. Magnetic resonance imaging and proton spectroscopic alterations correlate with parkinsonian signs in patients with cirrhosis. Gastroenterology 2000;119: 774-781.
20. Parson-Smith BG, Summerskill KHJ, Dawson AM, Sherlock S. The electroencephalograph in liver desease. Lancet 1957;2:867-871.
21. Vanhamme L, van den Boogaart A, Van Huffel S. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson 1997;129:35-43.
22. Magnetic Resonance User Interface Home Page [http://www.mrui. uab.es/mrui/].
23. van den Boogaart A, Van Hecke P, Van Huffel S, Graveron-Demilly D, van Ormondt D, de Beer R. MRUI: a graphical user interface for accurate routine MRS data analysis. In: Proceedings of the 13th Annual Meeting of ESMRMB, Prague, 1996. p 318.
24. Danielsen ER, Ross B. Magnetic resonance spectroscopy diagnosis of neurological diseases. New York: Dekker; 1999.
25. 1H NMR spectroscopy at 4 Tesla. In: Proceeedings of the 12th Annual Meeting of ISMRM, Kyoto, Japan, 2004. p 107.
26. Zieve L. Pathogenesis of hepatic encephalopathy. Metab Brain Dis 1987;2:147-165.
27. Butterworth RF, Giguere JF, Michaud J, Lavoie J, Layrargues GP. Ammonia: key factor in the pathogenesis of hepatic encephalopathy. Neurochem Pathol 1987;6:1-12.
28. Bachmann C. Mechanisms of hyperammonemia. Clin Chem Lab Med 2002;40:653-662.
29. 1H NMR spectroscopy in patients with chronic hepatic encephalopathy. Analysis of changes in cerebral glutamine, choline and inositols. NMR Biomed 1991;4:109-116.
30. Kreis R, Farrow N, Ross BD. Diagnosis of hepatic encephalopathy by proton magnetic resonance spectroscopy. Lancet 1990;336:635-636.
31. Geissler A, Lock G, Frund R, Held P, Hollerbach S, Andus T, Scholmerich J, Feuerbach S, Holstege A. Cerebral abnormalities in patients with cirrhosis detected by proton magnetic resonance spectroscopy and magnetic resonance imaging. Hepatology 1997;25:48-54.
32. Suarez I, Bodega G, Fernandez B. Glutamine synthetase in brain: effect of ammonia. Neurochem Int 2002;41:123-142.
33. Pouwels PI, Frahm I. Differential distribution of NAA and NAAG in human brain as determined by quantitative localized proton MRS. NMR Biomed 1997;10:73-78.
34. Vrenken H, Barkhof F, Uitdehaag BM, Castelijns JA, Polman CH, Pouwels PJ. MR spectroscopic evidence for glial increase but not for neuroaxonal damage in MS normal-appearing white matter. Magn Reson Med. 2005;53:256-66.
35. Jones EA. Ammonia, the GABA neurotransmitter system, and hepatic encephalopathy. Metab Brain Dis 2002;17:275-281.
36. Jones EA, Basile AS. Does ammonia contribute to increased GABA-ergic neurotransmission in liver failure? Metab Brain Dis 1998;13:351-360.
37. A receptor complex by ammonia: implications for the pathogenesis of hyperammonemic syndromes. Brain Res 1996;720:35-44.
38. Bender AS, Norenberg MD. Effect of ammonia on GABA uptake and release in cultured astrocytes. Neurochem Int 2000;36:389-395.
39. 1H-MR spectra of alcohol-dependent and hepatic encephalopathy patients. Am J Psychiatry 1999;156:952-954.